<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HB05C73201E2942DDB83B208B01A71140" public-private="public" bill-type="olc"> 
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 HR 2438 IH: To amend the Federal Food, Drug, and Cosmetic Act with respect to broader application of Bayesian statistics and adaptive trial designs.</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2015-05-19</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code> 
<congress>114th CONGRESS</congress>
<session>1st Session</session>
<legis-num>H. R. 2438</legis-num> 
<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber> 
<action> 
<action-date date="20150519">May 19, 2015</action-date> 
<action-desc><sponsor name-id="C001092">Mr. Collins of New York</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
</action> 
<legis-type>A BILL</legis-type> 
<official-title>To amend the Federal Food, Drug, and Cosmetic Act with respect to broader application of Bayesian statistics and adaptive trial designs.</official-title> 
</form> 
<legis-body id="H6AC39EBB1B754B55BC6B7821FEB93B10" style="OLC"> 
<section id="H90A47ACBA5734310B6A0732CEB0AD704" section-type="section-one" commented="no"><enum>1.</enum><header>Broader application of Bayesian statistics and adaptive trial designs</header> 
<subsection id="HC41921B8D12A41CA9F86B076874EBDD4" commented="no"><enum>(a)</enum><header>Proposals for use of innovative statistical methods in clinical protocols for drugs and biological products</header><text display-inline="yes-display-inline">For purposes of assisting sponsors in incorporating adaptive trial design and Bayesian methods into proposed clinical protocols and applications for new drugs under section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) and biological products under section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>), the Secretary shall conduct a public meeting and issue guidance in accordance with subsection (b).</text></subsection> <subsection id="H6D87499DC5924EAB857EFF3B1FCAD7A8" commented="no"><enum>(b)</enum><header>Guidance addressing use of adaptive trial designs and Bayesian methods</header> <paragraph id="HFAFD9329F2794ED88B5CE030E5263A90" commented="no"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs (in this subsection referred to as the <quote>Secretary</quote>), shall—</text> 
<subparagraph id="HBDA49A9F0CB141529C916D91E40BC1C7" commented="no"><enum>(A)</enum><text display-inline="yes-display-inline">update and finalize the draft guidance addressing the use of adaptive trial design for drugs and biological products; and</text></subparagraph> <subparagraph id="H8B63977BED9648BCB5EDD5C89E1F7E0E" commented="no"><enum>(B)</enum><text display-inline="yes-display-inline">issue draft guidance on the use of Bayesian methods in the development and regulatory review and approval or licensure of drugs and biological products.</text></subparagraph></paragraph> 
<paragraph id="H031693703B5B4C8E88B5438A8F4DA817" commented="no"><enum>(2)</enum><header>Contents</header><text>The guidances under paragraph (1) shall address—</text> <subparagraph id="H856709D4453B4DB9B71DC70DEE89F919" commented="no"><enum>(A)</enum><text display-inline="yes-display-inline">the use of adaptive trial designs and Bayesian methods in clinical trials, including clinical trials proposed or submitted to help satisfy the substantial evidence standard under section 505(d) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(d)</external-xref>);</text></subparagraph> 
<subparagraph id="HAE54008E21834B5EA4721EDDF1111584" commented="no"><enum>(B)</enum><text display-inline="yes-display-inline">how sponsors may obtain feedback from the Secretary on technical issues related to modeling and simulations prior to—</text> <clause id="HDC8B1702DEC54F52AF93389E708DAD2D" commented="no"><enum>(i)</enum><text>completion of such modeling or simulations; or</text></clause> 
<clause id="H2E88BA7987D645529C479CE14AA25AD8" commented="no"><enum>(ii)</enum><text>the submission of resulting information to the Secretary;</text></clause></subparagraph> <subparagraph id="H8F6C27A722CE4B29B40BEFAA9FB516DD" commented="no"><enum>(C)</enum><text display-inline="yes-display-inline">the types of quantitative and qualitative information that should be submitted for review; and</text></subparagraph> 
<subparagraph id="HD19E129B19364138BBAC00458EAA21F9" commented="no"><enum>(D)</enum><text display-inline="yes-display-inline">recommended analysis methodologies.</text></subparagraph></paragraph> <paragraph id="H3A42808EF4ED4346B82FCD7D2F36B254" commented="no"><enum>(3)</enum><header>Public meeting</header><text display-inline="yes-display-inline">Prior to updating or developing the guidances required by paragraph (1), the Secretary shall consult with stakeholders, including representatives of regulated industry, academia, patient advocacy organizations, and disease research foundations, through a public meeting to be held not later than 1 year after the date of enactment of this Act. </text></paragraph> 
<paragraph id="HDA0191B920A84BD2970654885C3EDBF1" commented="no"><enum>(4)</enum><header>Schedule</header><text>The Secretary shall publish—</text> <subparagraph id="H9CE34BC834EC4111A5F336B4EB879398" commented="no"><enum>(A)</enum><text>the final guidance required by paragraph (1)(A) not later than 18 months after the date of the public meeting required by paragraph (3); and</text></subparagraph> 
<subparagraph id="H36EAB1F464ED475C8E927789D24C6C15" commented="no"><enum>(B)</enum><text display-inline="yes-display-inline">the guidance required by paragraph (1)(B) not later than 48 months after the date of the public meeting required by paragraph (3).</text></subparagraph></paragraph></subsection></section> </legis-body> </bill> 

